Novel Rx
Dual seropositivity (rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA) as well as shared epitope (SE) are known to be associated with poor prognosis and structural damage in…
6 months 3 weeks ago
Biosimilar uptake across the world.
Interesting that rich countries use more biosimilars - presumably because they have bargaining power - and that means they can access even better pricing.
#EULAR2024 POS0597 Leiden @RheumNow https://t.co/wZgA0JH5uu
6 months 3 weeks ago
OP0201- clinical characteristics of pts failing ≥2 b/tsDMARDs
D2T RA pts characterised by
⏰ Earlier disease
⏰ Later initiation of DMARD therapy
Discontinuation of drugs mainly due to inefficacy regardless of number of drug lines or MOAs used
#EULAR2024 @RheumNow
6 months 3 weeks ago
#EULAR2024 OP0008 Phase 2 #Sjogren RCT Iscalimumab, anti-CD40mAb in two cohorts (1=High systemic activity; 2=High symptom burden but low systemic) showed sustained improvement in ESSDAI & ESSPRI at 48wks in ISC-ISC group, as well as those switched at 24wks from PBO-ISC @RheumNow https://t.co/GuifDHA0lK
6 months 3 weeks ago
#EULAR2024 OP0089 Promising data from Phase 2 RCT on dual blockade depletion & BAFF-R-i, Ianalumab in #lupus. After 24 wks double-blind, sustained response (SRI-4 + Pred ≤5mg/d or ≤ BL dose) was seen in IAN-IAN group while PBO-IAN improved in open label phase at 48wks @RheumNow https://t.co/MUo76ii4vB
6 months 3 weeks ago
12-week ARGO Phase 2 trial data of IL-17A- and IL-17F-inhibiting Nanobody sonelokimab delivers rapid onset and robust levels of clinical response, including high-threshold outcomes, compared with placebo in patients with active PsA, with a favorable benefit–risk profile. It met… https://t.co/4wj222FkzP https://t.co/ipUSjKvpuB
Systematic lupus erythematosus (SLE), a chronic autoimmune multi-system inflammatory condition, can present with various, sometimes severe, clinical manifestations, leading to high levels of…
6 months 3 weeks ago
OP0181- What are the best drugs to treat D2T RA?
In this cohort of 185 pts, switching biologic or JAKi improved disease activity & was considered to be effective for patients with D2TRA, regardless of mode of action
@RheumNow #EULAR2024
6 months 3 weeks ago
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.… https://t.co/HrRnoDzSPP https://t.co/Gp1KZmPych
Poster Hall